News - Cortado Ventures

Recent Cortado news, media & events

Blog Posts | Newsletters | Podcasts

Recent news & events

Fortune: What do VCs really want from the Fed

Feb 7, 2024 | Media

This article discusses the impact of the Federal Reserve's decision not to cut interest rates and its implications for various sectors, including venture capital (VC). The Federal Reserve's indication that rate cuts are unlikely in the near future has led to concern...

Nathaniel Harding: Year in Review and 2024 Outlook

Feb 1, 2024 | Blog

2023 Lookback for Cortado Ventures -- Read the full story here At Cortado Ventures, we’re excited for 2024. In our company meeting this week, we strategized our position in the Midcontinent market and what it will take to source, select, and support the best and most...

Why We Invested: Lumata Health

Jan 29, 2024 | Blog, Media, Portfolio Companies

Why We Invested: Lumata Health Pioneering Next-Generation Eye Care Authored by Cody Merrill At Cortado Ventures, we are in the venture capital business of maximizing risk-adjusted returns with high-potential, early-stage startups. We seek...

Cortado Ventures Invests in CorriXR

Jan 22, 2024 | Media

FOR IMMEDIATE RELEASE Jan. 16, 2024 Contact: Anthony Triana atriana@saxum.com (Direct) 405.818.0791 Cortado Ventures Invests in CorriXR: A Groundbreaking Gene-Editing Company with Initial Focus on Oncology OKLAHOMA CITY – Cortado Ventures, a...

Nathaniel Harding’s Ongoing Board Commitment

Jan 19, 2024 | Media

Congratulations to our Managing Partner, Nathaniel Harding for earning another term of service for the Greater Oklahoma City Chamber board. Board members, in roles like this, play a pivotal part in shaping the direction and policies of the organization. Nathaniel's...

Cadenza Bio, Inc. Secures $2.44M in Oversubscribed Series Seed Financing

Jan 4, 2024 | Blog

Preclinical biotechnology company initially focusing on therapeutic drug development to promote remyelination in Multiple Sclerosis OKLAHOMA CITY, Dec. 14, 2023 /PRNewswire/ -- Cadenza Bio, Inc. (Cadenza), a privately-held biotechnology company focused on developing...